Lifitegrast is a novel lymphocyte function-associated antigen 1 (LFA-1) antagonist. It acts by inhibiting LFA-1 interaction with the intercellular adhesion molecule (ICAM)-1 on the T-cell surface, inhibiting T-cell adhesion, migration, activation and subsequent cytokine release and thereby inhibiting subsequent T-cell-mediated inflammation associated with Dry Eye Disease.
Liftear Ophthalmic Solution: Each ml contains Lifitegrast INN 50 mg
Preservative: Sodium Perborate BP 0.01%
Lifitegrast is approved by USFDA for the treatment of the signs and symptoms of Dry Eye Disease (DED).
Instill one drop in the affected eye(s) twice daily (approximately 12 hours apart).
Lifitegrast ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product.
- For ophthalmic use only
- To avoid possible contamination of the drops, do not touch the dropper tip or to any surface
- If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications
- Contact lenses should be removed prior to the administration of Lifitegrast and may be reinserted 15 minutes following administration
The most common adverse reactions were instillation site irritation, dysgeusia and decreased visual acuity.
Use in pregnancy: There are no adequate data and well-controlled studies in pregnant women. Lifitegrast ophthalmic solution should be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.
Use in lactation: It is not known whether Lifitegrast is excreted in human milk. Caution should be exercised while giving this ophthalmic solution to a nursing mother.
Use in children: Safety and efficacy in pediatric patients below the age of 17 years have not been established.
Use in geriatric patients: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.
Liftear Ophthalmic Solution: Each LDPE dropper bottle contains 5 ml sterile & pyrogen free ophthalmic solution.
© 2023. Aristopharma Ltd. All rights reserved.